Natale, Ronald B.

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial

Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 2,517

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 645

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M.-J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., et al. (2020) · JAMA Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 623

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

Yang, J. C. H., Kim, S.-W., Kim, D.-W., Lee, J.-S., Cho, B. C., Ahn, J.-S., Lee, D. H., Kim, T. M., Goldman, J. W., Natale, R. B., et al. (2020) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 395

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

Mita, M., Fu, S., Piha-Paul, S. A., Janku, F., Mita, A., Natale, R., Guo, W., Zhao, C., Kurzrock, R., & Naing, A. (2017) · Investigational New Drugs

Melanoma and MAPK PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 26